Q4 FY26 revenue stabilization after 3 quarters of decline
Expected: March 2026MEDIUM confidence
Q4 results due in March 2026 could show top-line inflection after consecutive quarterly declines
“Q3 FY26 revenue down 9.72% YoY and 5.41% QoQ”
Syncom Formulations (India) Ltd: Stock Analysis & Fundamentals
Updated this weekSyncom Formulations (India) Ltd (Pharma - Others) — fundamental analysis, earnings data, and key metrics. PE: 14.9. ROE: 15.6%. This stock is not currently in the Nifty 500 momentum outperformers list.
What's Happening
💪Debt reduced 80% YoY — balance sheet strengthening
Re-Rating Catalysts
1. Q4 FY26 revenue stabilization after 3 quarters of decline
March 2026MEDIUM
2. Strategic partnership announcement
February-March 2026LOW
3. Asset monetization of land bank
Q2-Q3 FY27LOW
Value Trap Risks
1. Persistent revenue decline
HIGH2. Structural business challenges
HIGH3. Zero institutional interest
MEDIUMKey Numbers
Current Price
₹11
Market Cap
1.0K Cr
Valuation
N/AIs Syncom Formulations (India) Ltd a Turnaround Opportunity?
Deep value thesis based on recent earnings • Updated Feb 22, 2026
Exceptional margin expansion (OPM up 687 bps YoY) and zero-debt strength overshadowed by temporary revenue contraction creates a classic deep value opportunity.
Verdict
EARLY_INNINGS
What Could Re-Rate Syncom Formulations (India) Ltd?
Re-rating catalysts over the next 2-4 quarters • Updated Feb 22, 2026
Strategic partnership announcement
Expected: February-March 2026LOW confidence
Board meeting scheduled for February 12, 2026 to review Q3 FY26 financial results may signal new initiatives
“Board meeting scheduled for February 12, 2026 to review Q3 FY26 results”
Asset monetization of land bank
Expected: Q2-Q3 FY27LOW confidence
Balance sheet shows ₹4.56B total assets vs ₹3.78B equity, indicating potential hidden value
“Total assets of ₹4.56B vs equity of ₹3.78B per Simply Wall St data”
What Are the Value Trap Risks for Syncom Formulations (India) Ltd?
Risks that could prevent re-rating or deepen the value trap
Persistent revenue decline
HIGHContinued revenue decline in Q4 FY26
Management view: Company has tightened credit terms to improve collections but hasn't addressed top-line growth drivers.
Monitor: Q4 FY26 revenue growth
Structural business challenges
HIGHNo improvement in long-term growth trajectory
Management view: Management has focused on cost optimization but hasn't articulated a clear growth strategy.
Monitor: 3-year revenue CAGR trend
Zero institutional interest
MEDIUMNo institutional accumulation in coming quarters
Management view: Management hasn't engaged with institutional investors to address concerns.
Monitor: Q4 FY26 institutional holding data
What Is Syncom Formulations (India) Ltd's Management Guidance?
Forward-looking targets from management for FY26
Management Tone: CAUTIOUS
Key Milestones
• Q4 FY26 revenue stabilization
• Potential strategic partnership announcement
The above analysis is AI-generated from publicly available financial data. This is educational research only — not investment advice. Last updated Feb 22, 2026.
Frequently Asked Questions: Syncom Formulations (India) Ltd
Based on publicly available financial data. This is educational research, not investment advice.
What were Syncom Formulations (India) Ltd's latest quarterly results?
Syncom Formulations (India) Ltd's latest quarterly results (Dec 2025) show
- PAT Growth YoY: +46.2%
- Revenue Growth YoY: -10.2%
- Operating Margin: 18.0%
What is Syncom Formulations (India) Ltd's current PE ratio?
Syncom Formulations (India) Ltd's current PE ratio is 14.9x.
- Current PE: 14.9x
- Market Cap: 1.0K Cr
What is Syncom Formulations (India) Ltd's price-to-book ratio?
Syncom Formulations (India) Ltd's price-to-book ratio is 2.7x.
- Price-to-Book (P/B): 2.7x
- Book Value per Share: ₹4
- Current Price: ₹11
Is Syncom Formulations (India) Ltd a fundamentally strong company?
Syncom Formulations (India) Ltd's fundamental strength based on key financial ratios
- Return on Capital (ROCE): 19.0%
Is Syncom Formulations (India) Ltd debt free?
Syncom Formulations (India) Ltd has a debt-to-equity ratio of N/A.
- Total Debt: ₹1 Cr
What is Syncom Formulations (India) Ltd's return on equity (ROE) and ROCE?
Syncom Formulations (India) Ltd's return ratios over recent years
- FY2023: ROCE 10.0%
- FY2024: ROCE 11.0%
- FY2025: ROCE 19.0%
Is Syncom Formulations (India) Ltd's cash flow positive?
Syncom Formulations (India) Ltd's operating cash flow is positive (FY2025).
- Cash from Operations (CFO): ₹23 Cr
- Free Cash Flow (FCF): ₹5 Cr
- CFO/PAT Ratio: 47% (weak cash conversion)
What is Syncom Formulations (India) Ltd's dividend yield?
Syncom Formulations (India) Ltd currently does not pay a significant dividend (yield 0.00%).
- Dividend Yield: 0.00%
- Current Price: ₹11
Who holds Syncom Formulations (India) Ltd shares — promoters, FII, DII?
Syncom Formulations (India) Ltd's shareholding pattern (Dec 2025)
- Promoters: 50.6%
- FII (Foreign): 0.3%
- Public: 49.2%
Is promoter holding increasing or decreasing in Syncom Formulations (India) Ltd?
Syncom Formulations (India) Ltd's promoter holding has remained stable recently.
- Current Promoter Holding: 50.6% (Dec 2025)
- Previous Quarter: 50.6% (Sep 2025)
- Change: 0.00% (stable)
Is Syncom Formulations (India) Ltd a new momentum entry or an established outperformer?
Syncom Formulations (India) Ltd is an established outperformer with 1 weeks of consecutive Nifty 500 outperformance.
What are the growth catalysts for Syncom Formulations (India) Ltd?
Syncom Formulations (India) Ltd has 3 key growth catalysts identified from recent earnings analysis
- Q4 FY26 revenue stabilization after 3 quarters of decline
- Strategic partnership announcement
- Asset monetization of land bank
What are the key risks in Syncom Formulations (India) Ltd?
Syncom Formulations (India) Ltd has 3 key risks worth monitoring
- Persistent revenue decline
- Structural business challenges
- Zero institutional interest
What is Syncom Formulations (India) Ltd's management guidance for growth?
Syncom Formulations (India) Ltd's management has provided the following forward guidance for FY26
- Management tone: cautious
- Milestone: Q4 FY26 revenue stabilization
- Milestone: Potential strategic partnership announcement
Is Syncom Formulations (India) Ltd worth studying for long term investment?
Based on quantitative research signals, here is why Syncom Formulations (India) Ltd may be worth studying
- Cash flow is positive — CFO ₹23 Cr
What is the investment thesis for Syncom Formulations (India) Ltd?
Syncom Formulations (India) Ltd investment thesis summary:
Research Signals (Bull Case)
- Growth catalyst: Q4 FY26 revenue stabilization after 3 quarters of decline
Risk Factors (Bear Case)
- Key risk: Persistent revenue decline
What is the future outlook for Syncom Formulations (India) Ltd?
Syncom Formulations (India) Ltd's forward outlook based on current data signals
- Key Catalyst: Q4 FY26 revenue stabilization after 3 quarters of decline
- Key Risk: Persistent revenue decline
The above FAQs are generated from publicly available earnings data and conference call transcripts. This is educational research only. Sector Alpha is not SEBI registered and does not provide investment advice.